Trial intelligence / Profile preview

Surufatinib with or without TAE for neuroendocrine tumor liver metastases

ChiCTR2300071991Phase 3Not yet recruiting

Sponsor
West China Hospital of Sichuan University
Start
Apr 2023
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised, open-label trial of surufatinib in apudoma (NET) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: progression-free survival. Planned start Apr 2023; status: not yet recruiting.

02

Drugs

surufatinib
03

Conditions

apudoma (NET)

Beyond the preview

Go deeper on ChiCTR2300071991.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2300071991.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call